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Abstract
Fibrodysplasia Ossificans Progressiva (FOP) is a rare, heritable condition typified by progression of extensive ossification
within skeletal muscle, ligament and tendon together with defects in skeletal development. The condition is easily
diagnosed by the presence of shortened great toes and there is severe advancement of disability with age. FOP has been
shown to result from a point mutation (c.617G.A) in the ACVR1 gene in almost all patients reported. Very recently two
other mutations have been described in three FOP patients. We present here evidence for two further unique mutations
(c.605G.T and c.983G.A) in this gene in two FOP patients with some atypical digit abnormalities and other clinical
features. The observation of disparate missense mutations mapped to the GS and kinase domains of the protein supports
the disease model of mild kinase activation and provides a potential rationale for phenotypic variation.
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Introduction
Fibrodysplasia Ossificans Progressiva (FOP) is a rare, autosomal
dominant disease with complete penetrance involving the
progressive ossification of the skeletal muscles, fasciae, tendons
and ligaments. Smooth muscle and cardiac muscles remain
unaffected. Due to low reproductive fitness the condition is mainly
a result of spontaneous new mutations and it has a prevalence of
approximately one in two million individuals worldwide. FOP
shows no geographic, ethnic, racial or gender predisposition [1].
Individuals with FOP appear normal at birth except for great
toe abnormalities; these being short, deviated and later mono-
phalangic. Extensive fusion of the lateral masses of the cervical
vertebrae is often seen with hypoplasia of the vertebral bodies.
Femoral necks are abnormally wide and there may be true bone
exostoses additional to muscle ossification with short malformed
thumbs being less common [2,3]. Following periodic acute
episodes of mysositis, endochondral ossification of striated muscles
generally begins in the occipital, cervical and upper paraspinal
muscles and later affects most muscles around the major joints.
Minor trauma or viral illnesses can initiate acute inflammatory
mysositic episodes leading to progressive heterotopic ossification,
which is amplified by surgical intervention or removal. The
phenotype of FOP is affected by both genetic and environmental
factors with postnatal heterotopic ossification varying with life
history and environmental exposure [4]. Ossification occurs
progressively over the course of a lifetime in an inevitable episodic
and unpredictable manner with most patients being confined to a
wheelchair by the third decade of life and requiring lifelong care.
Recently the genetic cause of FOP was discovered within the
ACVR1 gene, which encodes a type I bone morphogenetic protein
(BMP) transmembrane receptor [5]. A single point mutation
(c.617G.A) was identified in all FOP patients studied. This non-
synonymous mutation causes an Arg206His amino acid substitu-
tion within the GS (glycine-serine rich) domain of the ACVR1
protein, and has been confirmed by our further work and also by
others [6,7]. Type I receptors such as ACVR1 are normally
inactive until binding of extracellular BMP stimulates their
phosphorylation by type II receptors within the GS domain. This
activates the type I protein to recruit and phosphorylate Smad
signalling molecules within the cell that subsequently cause gene
transcription or repression. The GS domain is also negatively
regulated through the binding of FKBP12, which provides a
mechanism to buffer the overall signal in the cell [8]. The switch
between the inactive and active states has been illustrated by
crystal structures of the type I TGF-beta receptor kinase domain as
well as its complex with FKBP12 [9,10].
It has been observed that the Arg206His mutation causes the
ACVR1 protein to be mildly constitutively active [11]. Since the
mutation occurs in the activating GS domain it has been suggested
that this promotes a shift in the absence of BMP towards the active
kinase structure causing over-activation of ACVR1 and subse-
quent R-Smad signalling cascades [5,12]. Recently other ACVR1
mutations have been reported in three FOP patients. A Japanese
PLoS ONE | www.plosone.org 1 March 2009 | Volume 4 | Issue 3 | e5005man with FOP has been reported with an ACVR1 mutation,
c.1067G.A resulting in a Gly356Asp amino-acid change in the
protein kinase domain [13]. In two Italian patients, a novel
mutation c.774G.C, leading to the Arg258Ser substitution in the
kinase domain of the ACVR1 receptor was seen. In a three-
dimensional model of the protein structure, Arg258 maps in close
proximity to the GS domain [14]. Here we report two patients
with expression of the major characteristics that define FOP, but
with some atypical features, that both lack the typical, specific
c.617G.A mutation and the other recently reported mutations
but present two different and separate coding mutations in ACVR1.
Methods
Patients
Patient 1 is female and was diagnosed clinically with FOP in
2003 aged 14 years. The first presentation was with a painful bony
lump over her right scapula after a fall and clinical examination
showed that there was only one short great toe with the other
normal. Subsequently she developed multiple tender bony
swellings, and the detection of toe abnormality confirmed the
diagnosis. Her right shoulder was fixed in internal rotation. Fixed
flexion deformities of both elbows were present. Her lumbar spinal
movements were restricted. The patient continued to have
frequent flares of the condition with increased inflammatory
lesions over her shoulder joints, neck, and jaw and fusion of the
neck within 6 months of clinical presentation. This progressive
formation of lesions which later ossify is characteristic to FOP.
However, the relatively late age of onset is unusual and the
malformation of only one great toe has yet to be documented in
another patient.
Patient 2 is a 52 year old female with FOP whose clinical
features were first reported in 1976 [15] and subsequently
reviewed later [15,16]. Severe reduction deformities in all digits
were noted at birth. Her first presentation of the disease was with
lumps, usually painful, on the occiput. By 6 years the patient had a
stiff spine and shoulders. By 14 years both elbows and the right hip
showed ectopic ossification. At 18 years the left hip showed ectopic
ossification and at 20 years there was ossification around the jaw
after dental extraction. At 26 years the patient had complete spinal
fixation, the shoulders were fixed in adduction, the elbows fixed in
flexion, hip movement restricted and fixed in slight flexion and the
jaw gape was 0.3cm. She showed mild cognitive impairment. In
addition, there was diffuse scalp hair thinning beginning at
14 years of age.
Genetic Analyses
Patient samples. Blood samples were collected from patients and
family members and from normal controls with informed consent.
Lymphoblastoid cell lines were a generous gift from Professor J M
Connor, Glasgow,UK.
DNA Isolation. Genomic DNA was isolated from EBV-
transformed cell lines or from peripheral blood samples using
the FlexigeneTM Kit (Qiagen Ltd, UK) according to the
manufacturer’s instructions. The resulting DNA was resuspended
in the elution buffer supplied in the kit.
Identification of mutations. PCR primers (MWG Biotech AG,
Edersberg, Germany) were designed to amplify exon 6 of ACVR1
which contains the c.617G.A mutation. The sample DNA was
amplified using PCR with optimized MgCl2 concentrations and
annealing temperatures using reagents from Sigma, UK. Ampli-
fied DNA was purified on filter plates (Millipore (UK) Ltd,
Watford, UK) and sequenced in both forward and reverse
directions with Big Dye version 3 using an automated sequencer
(ABI3100, Applied Biosystems, Warrington, UK). Subsequently
primers were designed for all 11 exons of ACVR1 which were
sequenced in both patients. To ensure that the mutations found in
the patients were those specifically present in patients with FOP
100 healthy controls were screened also. The mutation in patient 2
created a restriction site for the restriction enzyme StyI and
controls were screened for this site using a restriction fragment
length polymorphism. In patient 1, the mutation did not create a
restriction site and all individuals were screened by sequencing
exon 6 of ACVR1 as described above.
Restriction fragment length polymorphism. The restriction
enzyme StyI (New England Biolabs, Hitchin, UK) was used to
digest amplified ACVR1 exon 8 in patient 2 and healthy controls.
The reaction was left overnight at 37uC and analyzed by agarose
gel electrophoresis with ethidium bromide staining and a 100bp
ladder (New England Biolabs, Hitchin, UK).
Homology modelling
The crystal structure of the kinase domain of the type I TGF-
beta receptor (PDB code 1B6C) in complex with FKBP12 [9] was
used as a template to model ACVR1. The alignment was
performed with the program ICM [17] and used for homology
modelling of the native ACVR1 sequence using the same software.
The resulting model was then energy minimised and side-chain
movements were allowed to resolve clashes. Using this native
model, in silico mutations were introduced corresponding to those
described in this study. The mutation Gly328Glu required limited
loop sampling to resolve main-chain clashes resulting from the
insertion of a larger side chain. Models were visually inspected
before selection. Side-chain rotamer optimisation was performed
for all mutations as well as for neighbouring residues. Electrostatic
potential isosurfaces as implemented in ICM were calculated for
all the resulting models.
Figure 1. DNA sequencing electropherograms of a typical FOP
patient, and of atypical patients 1 and 2, at the positions of the
causative ACVR1 mutations.
doi:10.1371/journal.pone.0005005.g001
Novel ACVR1 Mutations in FOP
PLoS ONE | www.plosone.org 2 March 2009 | Volume 4 | Issue 3 | e5005Results and Discussion
The previously described c.617G.A mutation has been
confirmed in most UK FOP patients with characteristic features
of FOP, but was not present in either of the two patients described
here (Figure 1). Patient 1 is heterozygous for the novel mutation
c.605G.Ti nACVR1. Like the c.617G.A mutation, this
mutation is found within the GS domain of the ACVR1 protein,
but results in a new substitution Arg202Ile. Patient 2 is
heterozygous for the novel mutation c.983G.A found within
ACVR1, which results in a Gly328Glu substitution. This mutation
occurs outside the GS region in the kinase catalytic domain
(Figure 2).
To date there are no available crystal structures for the kinase
domain of ACVR1. To understand the structural implications of
the new mutations, we built homology models of the native and
mutated ACVR1 kinase domains using the closest available
structure of the TGF-beta receptor (PDB code 1B6C). Important-
ly, this TGF-beta receptor domain shares the same mechanism of
regulation and is highly similar in sequence to ACVR1 (66%
sequence identity) with no insertion or deletions in the aligned
sequence. Structural models must be interpreted carefully as
disease mutations can alter the wild-type structure.
The mutated residues in patient 1 and classical FOP patients
map to the same region in the ACVR1 model positioned in the
aGS2 helix immediately following the glycine-serine (GS) rich
loop. (Fig. 3A–D). The native residues, both arginines, are solvent
accessible, and their mutation will directly impact upon the
electrostatic property of the GS domain surface. In particular, the
Arg202Ile mutation occurs within the recognition site of ACVR1
for its inhibitor FKBP12. The aGS2 helix also packs above the
kinase L45 loop which determines Smad interaction. The striking
similarity to the classical FOP mutation is consistent with the
current disease model suggesting that FOP results from increased
kinase activity [11]. It is noteworthy that patient 1 has less severe
clinical features than a typical FOP patient. Interestingly, the
electrostatic potential is changed less by the substitution Arg202Ile
(patient 1) than by Arg206His (classical), when both are compared
to wild-type ACVR1 (Fig. 3B–D). Furthermore, Arg206 shows
greater interaction with the L45 loop including an invariant salt
bridge with Asp269. These subtle effects may be correlated with
the phenotypic differences.
Figure 2. A schematic of ACVR1 domain organization showing the position of mutations in patients 1 (Arg202Ile) and 2 (Gly328Glu)
with respect to the classical mutation (Arg206His).
doi:10.1371/journal.pone.0005005.g002
Figure 3. Homology models of ACVR1. (A) Wild-type ACVR1 kinase domain. The residues where mutations are described in this study are
represented as sticks (green, labelled). A ribbons representation of the GS-rich motif is highlighted in magenta. A purple frame marks the zoomed
area in panel E. (B) wild-type ACVR1 model rotated 90u around the X-axis to show the surface occluded upon binding of FKBP12 (shown both as
ribbons and surface coloured according to electrostatic potential). The green box denotes the positive patch seen in the model of wild-type ACVR1.
(C) and (D) mutations Arg202Ile and Arg206His are shown as ribbons, with the mutations indicated (same view as panel B). The predicted
electrostatic potential for each mutant protein is shown in the insert (framing is equivalent to the green box of panel B). (E) Mutation Gly328Glu
induces a significant conformational change in the loop where it is sited. One of the putative conformations is depicted in orange (wild-type loop
conformation shown in grey). In this example a potential direct interaction could be formed between the modelled loop and the GS-rich motif.
doi:10.1371/journal.pone.0005005.g003
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presented by patient 2 maps to the loop following helix aE in the
kinase domain, but is positioned in the three-dimensional structure
adjacent to the GS-rich loop (Fig. 3A, E). In this substitution the
introduction of an acidic residue (glutamic acid) will again change
the local electrostatic potential. The native loop sequence is
absolutely conserved between ACVR1 and the TGF-beta receptor
ensuring a reliable initial model. Here the structure adopts a well
formed hairpin-like loop and the introduction of a bulkier side
chain will force a local change in conformation (Fig. 3E). The
precise conformation (or dynamics) of the new loop is not trivial to
predict preventing reliable interpretation of a change in functional
state. Potentially, any perturbation could weaken GS-domain
interactions that maintain the inactive kinase conformation.
In conclusion, two unique mutations in the ACVR1 gene have
been detected in two FOP patients from the UK with some
atypical digit abnormalities and other clinical features. The
resultant mutations are likely to result in local structural changes
in the ACVR1 protein as revealed by interrogating homology
models of the native and mutated ACVR1 kinase domains. In
particular, the electrostatic surface potential of the ACVR1 GS
domain is predicted to be appreciably affected by these disparate
point mutations, promoting a shift in the equilibrium between the
inactive and active ACVR1 structures causing mild kinase
activation. The ACVR1 receptors would thus show reduced
ligand-dependence and result in variable receptor activity effects
causing the different phenotypic features observed. The identified
mutants present new targets for ACVR1 kinase inhibitors that
have shown potential to manage heterotopic ossification [18,19].
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